The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 3 , Pages 677-683 , September 2010

Endothelin A receptor blockade improves regression of flow-induced pulmonary vasculopathy in piglets

  • Olaf Mercier, MD

      Affiliations

    • Inserm U999, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
    • Corresponding Author InformationAddress for reprints: Olaf Mercier, MD, Inserm U999, Hôpital Marie Lannelongue, 133 Avenue de la Résistance, 92350 Le Plessis-Robinson, France.
    • ,
  • Edouard Sage, MD

      Affiliations

    • Laboratoire de Chirurgie Expérimentale UPRES-EA 2705, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
    • ,
  • Mohammed Izziki, PhD

      Affiliations

    • Laboratoire de Chirurgie Expérimentale UPRES-EA 2705, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
    • ,
  • Marc Humbert, MD, PhD

      Affiliations

    • Laboratoire de Chirurgie Expérimentale UPRES-EA 2705, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
    • ,
  • Philippe Dartevelle, MD

      Affiliations

    • Laboratoire de Chirurgie Expérimentale UPRES-EA 2705, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
    • ,
  • Saadia Eddahibi, PhD

      Affiliations

    • Laboratoire de Chirurgie Expérimentale UPRES-EA 2705, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France
    • ,
  • Elie Fadel, MD, PhD

      Affiliations

    • Laboratoire de Chirurgie Expérimentale UPRES-EA 2705, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France

Received 24 August 2009 ,Revised 6 December 2009 ,Accepted 1 January 2010.

References 

  1. Riedel M, Stanek V, Widimsky J, Prerovsky I. Long-term follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81:151–158
  2. Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, et al. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. Ann Thorac Surg. 2003;76:1457–1462
  3. Dartevelle P, Fadel E, Chapelier A, Macchiarini P, Cerrina J, Parquin F, et al. Angioscopic video-assisted pulmonary endarterectomy for post-embolic pulmonary hypertension. Eur J Cardiothorac Surg. 1999;16:38–43
  4. Hartz RS, Byrne JG, Levitsky S, Park J, Rich S. Predictors of mortality in pulmonary thromboendarterectomy. Ann Thorac Surg. 1996;62:1255–1259
  5. Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008;177:1122–1127
  6. Dartevelle P, Fadel E, Mussot S, Chapelier A, Hervé P, de Perrot M, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J. 2004;23:637–648
  7. Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest. 1993;103:685–692
  8. Azarian R, Wartski M, Collignon MA, Parent F, Hervé P, Sors H, et al. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med. 1997;38:980–983
  9. Yi ES, Kim H, Ahn H, Strother J, Morris T, Masliah E, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med. 2000;162(4 Pt 1):1577–1586
  10. Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. Circulation. 2006;113:2011–2020
  11. Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. Eur Respir J. 2000;15:440–448
  12. Moser KM, Braunwald NS. Successful surgical intervention in severe chronic thromboembolic pulmonary hypertension. Chest. 1973;64:29–35
  13. Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3:608–614
  14. Anderson EG, Simon G, Reid L. Primary and thromboembolic pulmonary hypertension: a quantitative pathological study. J Pathol. 1972;110:273–293
  15. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease; a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958;18:533–547
  16. Rondelet B, Kerbaul F, Motte S, van Beneden R, Remmelink M, Brimioulle S, et al. Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation. 2003;107:1329–1335
  17. Reddy VM, Wong J, Liddicoat JR, Johengen M, Chang R, Fineman JR. Altered endothelium-dependent responses in lambs with pulmonary hypertension and increased pulmonary blood flow. Am J Physiol. 1996;271:H562–H570
  18. Ovadia B, Reinhartz O, Fitzgerald R, Bekker JM, Johengen MJ, Azakie A, et al. Alterations in ET-1, not nitric oxide, in 1-week-old lambs with increased pulmonary blood flow. Am J Physiol Heart Circ Physiol. 2003;284:H480–H490
  19. Black SM, Fineman JR, Steinhorn RH, Bristow J, Soifer SJ. Increased endothelial NOS in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol. 1998;275:H1643–H1651
  20. Galiè N, Kim NH. Pulmonary microvascular disease in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc. 2006;3:571–576
  21. Mercier O, Sage E, de Perrot M, Tu L, Marcos E, Decante B, et al. Regression of flow-induced pulmonary arterial vasculopathy after flow correction in piglets. J Thorac Cardiovasc Surg. 2009;137:1538–1546
  22. Wu C, Decker ER, Blok N, Bui H, You TJ, Wang J, et al. Discovery, modeling, and human pharmacokinetics of N-(2 acetyl-4,6-dimethylphenyl)-3-(3,4-dimethylisoxazol-5-ylsulfamoyl)thiophene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. J Med Chem. 2004;47:1969–1986
  23. Perreault T, Berkenbosch JW, Barrington KJ, Decker ER, Wu C, Brock TA, et al. TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res. 2001;50:374–383
  24. Bresser P, Pepke-Zaba J, Jaïs X, Humbert M, Hoeper MM. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc. 2006;3:594–600
  25. Bonderman D, Nowotny R, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Klepetko W, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2599–2603
  26. Hoeper MM, Kramm T, Wilkens H, Schulze C, Schäfers HJ, Welte T, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest. 2005;128:2363–2367
  27. Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006;28:138–143
  28. Jaïs X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, et al. Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension Study Group Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008;52:2127–2134

 This work was supported by a grant from Pneumologie Developpement, France.

 Disclosures: None.

PII: S0022-5223(10)00031-0

doi: 10.1016/j.jtcvs.2010.01.004

The Journal of Thoracic and Cardiovascular Surgery
Volume 140, Issue 3 , Pages 677-683 , September 2010

Article Tools

* Image Usage & Resolution